Business
Eli Lilly's Obesity Drug Combo Shows Promising Results
Eli Lilly’s combination therapy of Mounjaro and Zepbound showed significant weight loss in mid-stage trials. The company plans to start Phase 3 trials soon.
Coverage timeline — 4 articles
CNBC
The Trump administration says the tariffs respond to countries failing to effectively ban the trade of goods produced using forced-labor practices.
2026-09-30 14:04 UTC
New Scientist
Tirzepatide, sold as Mounjaro and Zepbound, is our most potent weight-loss drug, but it can be made even more effective when combined with a complementary medicine
2026-09-30 14:15 UTC
STAT News
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
2026-09-30 14:15 UTC
CNBC
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
2026-09-30 14:15 UTC